ZA8681B - 1,2-dialkoxy-omega-trialkylammonium cationic surfactants - Google Patents

1,2-dialkoxy-omega-trialkylammonium cationic surfactants

Info

Publication number
ZA8681B
ZA8681B ZA8681A ZA8681A ZA8681B ZA 8681 B ZA8681 B ZA 8681B ZA 8681 A ZA8681 A ZA 8681A ZA 8681 A ZA8681 A ZA 8681A ZA 8681 B ZA8681 B ZA 8681B
Authority
ZA
South Africa
Prior art keywords
dialkoxy
omega
cationic surfactants
trialkylammonium cationic
carbons
Prior art date
Application number
ZA8681A
Other languages
English (en)
Inventor
Deborah Anne Eppstein
Philip Louis Felgner
Gordon Henry Jones
Richard Bolton Roman
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of ZA8681B publication Critical patent/ZA8681B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Developing Agents For Electrophotography (AREA)
ZA8681A 1985-01-07 1986-01-06 1,2-dialkoxy-omega-trialkylammonium cationic surfactants ZA8681B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68940785A 1985-01-07 1985-01-07

Publications (1)

Publication Number Publication Date
ZA8681B true ZA8681B (en) 1987-08-26

Family

ID=24768317

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA8681A ZA8681B (en) 1985-01-07 1986-01-06 1,2-dialkoxy-omega-trialkylammonium cationic surfactants

Country Status (8)

Country Link
EP (1) EP0187702B1 (ja)
JP (2) JPH0662517B2 (ja)
AT (1) ATE50983T1 (ja)
AU (1) AU594654B2 (ja)
CA (1) CA1288774C (ja)
DE (1) DE3669503D1 (ja)
NZ (1) NZ214716A (ja)
ZA (1) ZA8681B (ja)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
SE464448B (sv) * 1985-04-04 1991-04-29 Int Genetic Sciences Fusogen fosfolipidvesikel innehaallande ett kvaternaert ammoniumhydroxidsalt i membranet samt ett foerfarande foer dess framstaellning
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE4013632A1 (de) * 1990-04-27 1991-10-31 Max Planck Gesellschaft Liposomen mit positiver ueberschussladung
DK0550463T3 (da) * 1990-09-06 1996-11-04 Johnson & Son Inc S C Fremgangsmåde til stabilisering af liposomer samt sammensætninger indeholdende dem
GB2250998A (en) * 1990-12-21 1992-06-24 Unilever Plc Cosmetic cleansing composition
JP3594962B2 (ja) * 1992-04-03 2004-12-02 コスモフェルム ベースローテン フェンノートシャップ アミノアルコールの選択的n‐アシル化
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
JPH07308570A (ja) * 1994-05-16 1995-11-28 Hirotaka Hirata 界面活性物質を含む分子複合体
CA2237316C (en) * 1995-11-30 2012-06-26 Vical Incorporated Complex cationic lipids
DE19605175A1 (de) 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
ATE395904T1 (de) 1996-09-13 2008-06-15 Lipoxen Technologies Ltd Liposome
US7384923B2 (en) 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
EP1829856A3 (en) 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US7432371B2 (en) 2002-02-07 2008-10-07 Covalent Partners, Llc Nanofilm and membrane compositions
EP1356820A1 (en) 2002-04-26 2003-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) DNA vaccine combined with an inducer of tumor cell apoptosis
JP2006273341A (ja) * 2005-03-28 2006-10-12 Toppan Printing Co Ltd 乾燥能力インジケーター機能付蓋
JP5072275B2 (ja) 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
EP2069378B1 (en) 2006-10-06 2016-10-05 The Scripps Research Institute Dna composition for eliciting an immune response against tumor-associated macrophages
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
WO2009129387A2 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
CA2756070C (en) 2009-03-27 2019-08-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kanamycin antisense nucleic acid for the treatment of cancer
WO2011064790A1 (en) * 2009-11-30 2011-06-03 Avra Laboratories Pvt. Ltd A novel process for making aliskiren, its novel intermediates and certain novel compounds
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
CA2792956C (en) 2010-03-17 2021-11-16 Socpra - Sciences Et Genie, S.E.C. Bacterial vaccine components from staphylococcus aureus and uses thereof
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
JP5902617B2 (ja) 2010-04-28 2016-04-13 協和発酵キリン株式会社 カチオン性脂質
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
JP2013095755A (ja) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
AU2012353463B2 (en) 2011-12-12 2017-08-24 Kyowa Hakko Kirin Co., Ltd. Lipid nanoparticles containing combinations of cationic lipids
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
US9913907B2 (en) 2012-07-16 2018-03-13 Kyowa Hakko Kirin Co., Ltd. RNAi pharmaceutical composition for suppressing expression of KRAS gene
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
TW201726614A (zh) 2015-12-25 2017-08-01 Kyowa Hakko Kirin Co Ltd 作為陽離子性脂質之化合物
ES2811523T3 (es) 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
BR112019007796A2 (pt) 2016-10-21 2019-09-03 Socpra Sciences Et Genie Sec construção de vacina e seus usos contra infecções causadas por staphylococcus
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
WO2022047176A2 (en) 2020-08-28 2022-03-03 University Of Houston System Single-chain coronavirus viral membrane protein complexes
US20220185852A1 (en) 2020-12-11 2022-06-16 Bayer Animal Health Gmbh Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
CN116003271B (zh) * 2022-12-13 2025-08-29 江西品信药业股份有限公司 一种季铵类脂质的合成方法
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567729A (en) * 1968-01-12 1971-03-02 Swift & Co Diquaternary ammonium halides

Also Published As

Publication number Publication date
AU5185386A (en) 1986-07-17
ATE50983T1 (de) 1990-03-15
JP2546623B2 (ja) 1996-10-23
JPH0770011A (ja) 1995-03-14
JPS61161246A (ja) 1986-07-21
JPH0662517B2 (ja) 1994-08-17
CA1288774C (en) 1991-09-10
EP0187702B1 (en) 1990-03-14
NZ214716A (en) 1989-04-26
DE3669503D1 (de) 1990-04-19
AU594654B2 (en) 1990-03-15
EP0187702A1 (en) 1986-07-16

Similar Documents

Publication Publication Date Title
NZ214716A (en) 1,2-dialkoxy-omega-trialkylammonium cationic surfactants
HU906029D0 (en) Process for the preparation of pleuromuthylyne derivatives
AU586691B2 (en) Diamino-androstane derivatives, process for their preparation and pharmaceutical compositions containing them
EP0132845A3 (en) Novel 1,8-naphthyridine derivatives, and process for preparation thereof
AU2722288A (en) Certain 3-substituted 2-alkyl benzofuran derivatives
HUT59693A (en) Process for producing morpholinyl derivatives of doxorubicin and pharmaceutical compositions containing them
ATE96446T1 (de) Estramustin-ester.
AU576926B2 (en) Tetrazole derivatives
AU631671B2 (en) 2-(2-vinylpyrrolidinylthio)carbapenem derivatives
DE3864336D1 (en) Aromatische thioaether.
IL78625A0 (en) Furanone derivatives and their preparation
IL106934A0 (en) Heteroarenylpiperazines,a process for their preparation and their use as medicaments